Sight Sciences Prevails in Patent Infringement Case Against Alcon
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy SGHT?
Source: Newsfilter
- Court Ruling Outcome: The U.S. District Court for Delaware upheld the jury's finding of willful infringement by Alcon, ordering them to pay $34 million in damages, which underscores Sight Sciences' robust intellectual property protection capabilities.
- Ongoing Revenue Assurance: The ruling mandates that Alcon pay a 10% ongoing royalty on Hydrus sales until November 10, 2028, providing Sight Sciences with a stable revenue stream and enhancing its financial stability moving forward.
- Damages Breakdown: The $34 million in damages includes $5.5 million in lost profits and $28.5 million in royalties, reflecting the strong market performance of the Hydrus product and its positive impact on Sight Sciences' financials.
- Legal Fee Expectations: Sight Sciences anticipates a $5.4 million success fee to Cooley LLP, which will be recorded as operating expenses but excluded from non-GAAP adjusted operating expenses, highlighting the company's commitment to legal matters and its implications for future investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGHT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGHT
Wall Street analysts forecast SGHT stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 3.660
Low
6.00
Averages
9.35
High
12.00
Current: 3.660
Low
6.00
Averages
9.35
High
12.00
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sight Sciences Prevails in Patent Infringement Case Against Alcon
- Court Ruling Outcome: The U.S. District Court for Delaware upheld the jury's finding of willful infringement by Alcon, ordering them to pay $34 million in damages, which underscores Sight Sciences' robust intellectual property protection capabilities.
- Ongoing Revenue Assurance: The ruling mandates that Alcon pay a 10% ongoing royalty on Hydrus sales until November 10, 2028, providing Sight Sciences with a stable revenue stream and enhancing its financial stability moving forward.
- Damages Breakdown: The $34 million in damages includes $5.5 million in lost profits and $28.5 million in royalties, reflecting the strong market performance of the Hydrus product and its positive impact on Sight Sciences' financials.
- Legal Fee Expectations: Sight Sciences anticipates a $5.4 million success fee to Cooley LLP, which will be recorded as operating expenses but excluded from non-GAAP adjusted operating expenses, highlighting the company's commitment to legal matters and its implications for future investments.
See More
SIGHT SCIENCES: 10% ROYALTY ON HYDRUS REVENUE GRANTED UNTIL NOVEMBER 10, 2028
Award Announcement: A significant award has been granted to the organization for its contributions to science.
Revenue Share: The organization will receive 10% of the revenue generated from Hydrus through November 10, 2028.
See More
SIGHT SCIENCES: $34 MILLION IN MONETARY DAMAGES AWARDED, ALONG WITH ADDITIONAL DAMAGES AND INTEREST, FOR PRIOR INFRINGEMENT
Monetary Damages Awarded: A total of $34 million in monetary damages has been awarded for past infringement.
Supplemental Damages and Interest: Additional supplemental damages and interest have also been included in the award.
See More
SIGHT SCIENCES: POST-TRIAL MOTIONS RULING UPHOLDS JURY VERDICT AND GRANTS FINANCIAL COMPENSATION TO CO
Post-Trial Motions: The court has issued an order regarding post-trial motions that preserves the jury's verdict.
Monetary Damages: The order also addresses the monetary damages awarded to the parties involved in the case.
See More
SIGHT SCIENCES: U.S. DISTRICT COURT RULING ON POST-TRIAL MOTIONS IN PATENT INFRINGEMENT LAWSUIT AGAINST ALCON INITIATED ON SEPTEMBER 16, 2021
Court Order Issued: A U.S. District Court has issued an order regarding post-trial motions in a patent infringement case.
Case Background: The patent infringement case was originally filed against Alcon on September 16, 2021.
See More
Investigation into Sight Sciences Investor Claims
- Financial Performance Disclosure: On March 4, 2026, Sight Sciences reported its Q4 and full-year 2025 financial results, projecting total revenue for FY 2026 to be between $82 million and $88 million, including $5 million to $7 million from Interventional Dry Eye, highlighting both challenges and opportunities in the market.
- Stock Price Decline Impact: Following the financial disclosures, Sight Sciences' common stock experienced a significant decline, undermining investor confidence in the company's future prospects and potentially leading to investor losses, raising questions about the company's compliance with securities laws.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Sight Sciences' executives violated federal securities laws, suggesting that investors who suffered losses during this period may have legal recourse, indicating potential reputational risks for the company.
- Investor Rights Protection: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients, demonstrating its capability and influence in protecting investor rights, which may encourage more affected investors to join the investigation.
See More
Sight Sciences Prevails in Patent Infringement Case Against Alcon
- Court Ruling Outcome: The U.S. District Court for Delaware upheld the jury's finding of willful infringement by Alcon, ordering them to pay $34 million in damages, which underscores Sight Sciences' robust intellectual property protection capabilities.
- Ongoing Revenue Assurance: The ruling mandates that Alcon pay a 10% ongoing royalty on Hydrus sales until November 10, 2028, providing Sight Sciences with a stable revenue stream and enhancing its financial stability moving forward.
- Damages Breakdown: The $34 million in damages includes $5.5 million in lost profits and $28.5 million in royalties, reflecting the strong market performance of the Hydrus product and its positive impact on Sight Sciences' financials.
- Legal Fee Expectations: Sight Sciences anticipates a $5.4 million success fee to Cooley LLP, which will be recorded as operating expenses but excluded from non-GAAP adjusted operating expenses, highlighting the company's commitment to legal matters and its implications for future investments.
See More
SIGHT SCIENCES: 10% ROYALTY ON HYDRUS REVENUE GRANTED UNTIL NOVEMBER 10, 2028
Award Announcement: A significant award has been granted to the organization for its contributions to science.
Revenue Share: The organization will receive 10% of the revenue generated from Hydrus through November 10, 2028.
See More
SIGHT SCIENCES: $34 MILLION IN MONETARY DAMAGES AWARDED, ALONG WITH ADDITIONAL DAMAGES AND INTEREST, FOR PRIOR INFRINGEMENT
Monetary Damages Awarded: A total of $34 million in monetary damages has been awarded for past infringement.
Supplemental Damages and Interest: Additional supplemental damages and interest have also been included in the award.
See More
SIGHT SCIENCES: POST-TRIAL MOTIONS RULING UPHOLDS JURY VERDICT AND GRANTS FINANCIAL COMPENSATION TO CO
Post-Trial Motions: The court has issued an order regarding post-trial motions that preserves the jury's verdict.
Monetary Damages: The order also addresses the monetary damages awarded to the parties involved in the case.
See More
SIGHT SCIENCES: U.S. DISTRICT COURT RULING ON POST-TRIAL MOTIONS IN PATENT INFRINGEMENT LAWSUIT AGAINST ALCON INITIATED ON SEPTEMBER 16, 2021
Court Order Issued: A U.S. District Court has issued an order regarding post-trial motions in a patent infringement case.
Case Background: The patent infringement case was originally filed against Alcon on September 16, 2021.
See More
Investigation into Sight Sciences Investor Claims
- Financial Performance Disclosure: On March 4, 2026, Sight Sciences reported its Q4 and full-year 2025 financial results, projecting total revenue for FY 2026 to be between $82 million and $88 million, including $5 million to $7 million from Interventional Dry Eye, highlighting both challenges and opportunities in the market.
- Stock Price Decline Impact: Following the financial disclosures, Sight Sciences' common stock experienced a significant decline, undermining investor confidence in the company's future prospects and potentially leading to investor losses, raising questions about the company's compliance with securities laws.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Sight Sciences' executives violated federal securities laws, suggesting that investors who suffered losses during this period may have legal recourse, indicating potential reputational risks for the company.
- Investor Rights Protection: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients, demonstrating its capability and influence in protecting investor rights, which may encourage more affected investors to join the investigation.
See More
